CUPERTINO, Calif., Jan. 27 /PRNewswire/ -- CardioThoracic Systems, Inc.
(CTS) (Nasdaq: CTSI) introduced the new FloCoil(TM) Shunt during the Society
of Thoracic Surgeons (STS) Conference currently taking place in New Orleans,
LA. The FloCoil Shunt, for which CTS recently received U.S. Food and Drug
Administration (FDA) 510(k) marketing clearance, is designed to facilitate a
bloodless field during minimally invasive (beating heart) bypass surgery while
maintaining myocardial perfusion.
The company believes the FloCoil's unique coil design enables a smooth
insertion and removal from the anastomosis site. Once in place, the CTS shunt
optimizes both perfusion and occlusion, facilitating a clean, bloodless field.
When the anastomosis is ready to be closed, a gentle pull on the radiopaque
tab (life ring) provides atraumatic removal of the FloCoil from the artery.
"Because of its unique design, the CTS FloCoil Shunt is a significant
advancement from the shunts currently available to surgeons," stated Rich
Ferrari, CTS president and CEO. "It is a beneficial tool in minimally
invasive bypass procedures as it allows for continuous coronary blood flow to
the myocardium while the surgeon is performing the anastomosis."
The FloCoil Shunt is available in nine sizes to accommodate various
coronary arteries.
CardioThoracic Systems, Inc., Cupertino, Calif., is a leading developer of
proprietary technologies in minimally invasive cardiothoracic surgery. The
company's current products are designed to enable cardiothoracic surgeons to
perform minimally invasive bypass surgery on a beating heart. CTS is also
developing technologies for the areas of minimally invasive valve repair and
replacement and saphenous vein harvesting. The company's stock is traded on
the Nasdaq Stock Market under the symbol CTSI.
This news release contains forward-looking information that involves risks
and uncertainties, including uncertainties associated with the capabilities
and clinical performance of the CTS FloCoil Shunt, the market acceptance of
CTS products, procedures and programs and the success of the company's
development efforts. Actual results may differ significantly from the results
discussed in the forward-looking statements as a result of those and other
factors, including factors set forth in the company's annual report on Form
10-K filed with the Securities and Exchange Commission on March 31, 1997 and
the company's most recent quarterly report on Form 10-Q filed with the
Securities and Exchange Commission on November 7, 1997. Copies of the Annual
Report on Form 10-K are available by calling the company's investor relations
department at 408/342-1700.
For more information on CardioThoracic Systems, Inc. via fax at no cost,
dial 800/PRO-INFO or 908/544-2850 outside the U.S. Ticker symbol: CTSI.
SOURCE CardioThoracic Systems, Inc.
 back to top
CONTACT:
Media: Christine Carbone, Director of
Marketing Communications, 408-342-1700, or Investors: Steve Van
Dick, CFO, 408-342-1700 both of CardioThoracic Systems, Inc.; or
General Information: Ann Trunko, Analysts: Kate Rajeck, both of
The Financial Relations Board, 415-989-1591
|
